Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06067568 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT06067568 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 50 participants.
The verdict
NCT06067568, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.
Interventions
- DRUG Lutikizumab Dose A
- DRUG Lutikizumab Dose B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2024-02-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06067568
The ClinicalTrials.gov registry entry for NCT06067568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lutikizumab Dose A is the first listed.
NCT06067568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06067568 about?
NCT06067568 is a clinical study titled "Relative Bioavailability of Two Lutikizumab Formulations and Pharmacokinetics, Safety, and Tolerability of Lutikizumab in Chinese Participants". The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.
What is the current status of trial NCT06067568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-28. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT06067568?
The interventions under investigation include: Lutikizumab Dose A (DRUG), Lutikizumab Dose B (DRUG).
Who is sponsoring clinical trial NCT06067568?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.